AstraZeneca PLC Stock Flat Friday
阿斯利康(AZN.US)PD-1/TIGIT双抗启动III期临床
阿斯利康(AZN.US)“奥希替尼”在中国获批新适应症
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
Reported Wednesday, HUTCHMED And AstraZeneca's ORPATHYS-TAGRISSO Therapy Advances In China With Priority NDA Status For MET-Amplified Lung Cancer
Takeda-backed Ascentage Pharma Files for $100M IPO
大摩:个体化癌症疫苗和ADC将成为2025年肿瘤治疗行业主要催化剂
Is AstraZeneca PLC (AZN) Among the U.K. Dividend Aristocrats for 2024?
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Daiichi Sankyo Gets Japanese Approval for Datroway
Here's Why Astrazeneca (AZN) Is a Strong Value Stock
Syncona: Achilles Announces Sale Of Technology Assets To AstraZeneca - Quick Facts
东方证券:首予和黄医药“买入”评级 目标价33.24港元
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC
Achievements and Progress Heading Into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
AstraZeneca's (LON:AZN) Investors Will Be Pleased With Their Respectable 55% Return Over the Last Five Years
ROSEN, LEADING INVESTOR COUNSEL Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AZN
AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe Into Fraud and Corruption - Hagens Berman
AstraZeneca PLC ADR Underperforms Tuesday When Compared To Competitors